Auxilius的动态

OM Pharma and Orphalan share insights on key considerations, realized benefits, and operational impact with a modern RIM platform. Join live discussion and Q&A 26 November to hear best practices for gaining visibility and control over the end-to-end submission process and increasing data quality. https://bit.ly/3UHe8k5 #RIM #RegulatoryOperations

Struggling with document exchange inefficiencies in your Pharma HUB Services? We've highlighted some of the most common challenges Pharma HUB Services face with paper-based document exchange processes, which can slow you down, frustrate patients, and even impact your bottom line. ?? Read the full blog to find out how you can overcome these challenges and improve your operations. https://bit.ly/3zXCVZl

The CDMO industry is challenged with increased competition, demand for manufacturing capacity, and growing pressure from CDMO customers to accelerate technology transfers to expedite drug product production and bring novel products to the clinic. Addressing these challenges may be easier than you think: L7|ESP? is a single unified process and data platform that standardizes and automates process development, technology transfer, manufacturing, and material management workflows while centralizing then contextualizing data across the entire product lifecycle.?L7|ESP supports greater business insight by providing comprehensive visibility and traceability across the entire product lifecycle. The platform allows CDMOs to monitor and document every step of the development and manufacturing process, ensuring compliance with regulatory requirements. Explore L7|ESP: https://bit.ly/3Vl4CSY

Today is the last day of exhibits at Asembia 2024! There is still time to come by the ConcertAI booth, #1518 to learn more about innovations in commercial data management. Here’s what Faith DeFreitas, Director, Business Intelligence Technology, is excited to showcase at Asembia: “ConcertAI’s comprehensive suite of web-based applications is tailored for pharmaceutical companies with specialty products and provides insights into key commercial performance metrics about the patient journey and brand performance. Our solutions utilize integrated data sets to explore metrics inside and outside the SP and Hub network, which illuminate the entire patient experience. Speak with us to learn more about how we empower field teams with predictive analytics and real-time alerts to proactively address patient onboarding challenges and streamline workflows of patient support program teams with our copilot solution." #Asembia2024 #PatientAnalytics #CommercialSystems #DataAggregation

At Flowtrial, we champion a holistic approach to clinical trials. Why? Because understanding the complete landscape is key to success. ? Holistic Oversight Means: ? Clarity: Seeing beyond immediate tasks for better insights. ? Proactivity: Foreseeing obstacles, crafting early solutions. ? Cohesiveness: Ensuring that each aspect of the trial synergizes with others. Our holistic method ensures every phase of your trial is interconnected and optimized for success. Ready to see your clinical trials thrive with a holistic strategy? Let’s connect! #Flowtrial #ClinicalTrials #HolisticApproach #Innovation #RiskManagement #Pharma #SponsorOversight #GCP #clinicalresearch #clinicaloversight

Thoughts on this? >> Icahn gives up seat on Illumina board, backing away from challenge to diagnostics company >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #pharmaceutical #pharma #productmarketing #biotech

Thoughts on this? >> Icahn gives up seat on Illumina board, backing away from challenge to diagnostics company >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #productmarketing #pharmaceutical #pharma #biotech

A rare chance to invest in the pre-IPO round of a new drug entering Phase III clinical trials: Pharmamel, a company developing a potential blockbuster therapeutic for #Sepsis, opens a 2 million euro tranche for private investors. Pharmamel's unique technology, based on injectable Melatonin, has already proven its worth in Phase II clinical trials for Sepsis: - Hospital stay reduced by 20% - Mortality rate reduced by 40% - No signs of toxicity or side effects The company prepares an IPO for Q4 2024, with the intention of offering significant liquidity and profits within 24 months. Whether you're interested in tackling Sepsis (arguably the number one cause of death globally) or in making a financial profit, this investment could be for you. More information -> https://lnkd.in/dKccBZq4

Interested in learning about the latest clinical findings shaping patient care, pharma and finance? Tune into this Oracle-hosted webinar featuring experts from across the life sciences industry. https://lnkd.in/d5Xhgwyi

???????? ???????? ?????? ?????? ???????????? ?????????????????? ????????????, ?????????? ?????? ???????????????? ?????????????? ???????? ???????????????? ???? ???? ??????????????????????. In a landscape where some CDMO and pharma giants are making massive investments in new facilities, smaller and midsized CDMOs should thrive by leveraging their unique strengths. While others might boast of physical expansion, emphasize your expertise, agility, and personalized service. Highlight your innovative approaches, specialized capabilities, your top scientific talent, and proven track record. Effective messaging around your distinct value propositions will set you apart and attract clients seeking tailored solutions. Remember, it's not all about size—it's about showcasing your capacity to deliver exceptional results. Bigger can even be viewed *negatively* during this era of such consolidation and clients getting lost in the shuffle.